View clinical trials related to Carcinoma, Renal Cell.
Filter by:Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. The goal of this cohort study is to identify prognostic factors, construct predictive nomograms, and optimize management for sporadic BRCC patients. The main questions it aims to answer are: What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients? Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.
To evaluate the safety of reoperation in patients with renal tumors who have ipsilateral tumor recurrence after nephron-sparing partial nephrectomy.
In France, the second cancer plan of 2009-2013 aimed to strengthen the role of MT by putting it back at the center of patient monitoring, in particular by asking "regional health agencies to encourage and support local experiments" which aim for better coordination between the city and the hospital. The third cancer plan for 2014-2019 insists on this measure because it had proven to be unproductive, and recommends, in addition to the creation of a nurse dedicated to the coordination of care between community medicine and the hospital, the creation of a direct telephone line to reach the hospital medical team. This measure is mainly aimed at the follow-up of certain cancers that do not require the technical support of the hospital, as is the case in the post-operative follow-up of RCC and CaP, where the additional examinations carried out during follow-up are carried out in the city. The research hypothesis is that this new method of monitoring had a positive impact on care in terms of quality, accessibility, organization and costs.
The purpose of the CAPABLE study is to compare health-related quality of life in renal cell carcinoma patients who use or do not use a mobile-based application to monitor adverse events for cancer treatment at home. As secondary objectives, the study investigates the usability of the system and its generalizability to other cancer types
Patients with renal cell carcinoma who were admitted to the First Affiliated Hospital of Sun Yat-sen University from February 1, 2021, to February 1, 2022, and met the following inclusion and exclusion criteria were collected. Clinical factors influencing the prognosis of enrolled patients were retrospectively analyzed, and a predictive system was established based on this. (Inclusion criteria: pathology of the surgical specimen confirmed the diagnosis of pRCC,b: age 18 years or older, c: localized RCC underwent radical nephrectomy or partial nephrectomy in our center. Exclusion criteria:a: lack of original CT images, b: patients with malignant tumors of other systems, c: patients who lost follow-up.)
Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.
Patients' outcome was studied after surgery for renal cell carcinoma. The primary outcome was overall survival and desease free survival. Secondary outcame was complications to surgery.
The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese patients with indeterminate renal masses or Suspected Recurrent Renal Clear Cell Carcinoma
The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC. The study includes participants who: - are 18 years old or above and have mRCC - took medicines that use the bodies immunity to fight against cancer as their first choice of treatment - took other medicines after taking the above first choice of treatment This is a study that looks into the data collected through a particular database from selected academic clinical sites participating in this study. The data of interest include: - the length of time between the start of a patient's treatment and the end of treatment - the length of time between the start of treatment and death - physician assessment of a patient's response to treatment We will compare the experiences of people receiving different combinations of treatments and see if there are any differences in the effectiveness of these medicines.
A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of Sunitinib Malate Capsules produced by Pfizer and Chia Tai Tianqing Pharmaceutical Group Co., Ltd, respectively.